Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance

Amylx Pharmaceuticals IncTrade
Vanguard Real Estate Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Vanguard Real Estate Index Fund ETF trades at $96.4. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.

AMLXVNQ
Market Cap
$2.64B
Sector
Health
52-Week High
$24.19$100.95
52-Week Low
$7.82$87.00
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Vanguard Real Estate Index Fund ETF

VNQ, the Vanguard Real Estate ETF, trades at $97.13, up 0.02% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. The ETF offers a dividend of $0.86 scheduled for June 2026, but key valuation ratios like P/E and P/B are unavailable. Recent news highlights institutional selling and comparisons with global real estate ETFs, emphasizing VNQ's U.S. REIT focus and low fees.

Outlook: VNQ faces headwinds from bearish technicals and institutional outflows, but its low expense ratio and U.S. real estate exposure provide stability. Risks include interest rate sensitivity and underperformance versus broader markets, as noted in long-term return comparisons. Investors should weigh dividend income against sector volatility and macroeconomic factors.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Vanguard Real Estate Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.

Read more on VNQ